Latest ArticlesAmorphous solid dispersion is one of the most effective formulation approaches to enhance the oral bioavailability of poorly water-soluble drugs with wide application prospects. However, due to the “aging”, a solid state physical stability problem, which affects the dissolution in vitro and absorption in vivo, the development of amorphous solid dispersion-based preparations faces great challenges. The solid state physical stability is affected by many factors such as formulation composition, preparation process and storage conditions. In this paper, formulation composition, preparation process and quality control of amorphous solid dispersion-based preparations are summarized in order to provide the guidance for the development of amorphous solid dispersion-based preparations.
Proteolysis targeting chimeras(PROTACs) are currently one of the hot spots in antineoplastic agent research. They have efficient and durable anti-tumor effects, good selectivity, and low possible toxicity. This review summarizes the research progress of new PROTAC drugs targeting estrogen receptors, androgen receptors, BCR-ABL, histone deacetylase 4, methyltransferase-like 3.
Oral administration is by far the most commonly used route of drug administration. Through the rational design and optimization of oral formulations and their preparation processes, increase of solubility, sustained- and controlled-release of drugs can be achieved, resulting in improved oral bioavailability, enhanced efficacy, reduced toxicity or personalized drug delivery. However, the current formulation and preparation process optimization of oral formulations is still highly dependent on traditional trial-and-error experiments and empirical data, which is time-consuming, laborious, costly, and hardly predictable. Artificial intelligence(AI) technology, which has flourished in recent years, is expected to enable efficient and systematic design of oral formulations. Based on the existing experimental data for oral preparations, a prediction model can be established through AI to predict the relevant indicators of oral preparations and optimize the process parameters of oral preparations. This review summarizes the basic principles and applications of AI-assisted development in oral formulations, discusses and offers prospects on the applications of AI in the field of oral formulations, and provides a reference for accelerating further research and development of pharmaceutical preparations with AI technology.
In view of the discovery of nitrosamine impurities in angiotensinⅡ receptor antagonists, histamine 2 receptor antagonists, antimicrobial drugs, antidiabetic drugs and other drugs, global regulatory agencies have significantly increased their supervision on nitrosamine impurities. Regulatory agencies in various countries have successively issued the corresponding guiding documents, developed risk assessment methods, and proposed control strategies for nitrosamine impurities in drugs. China has also successively introduced a series of guiding documents that are in line with the international standards to control nitrosamine impurities. However, in practical work, there are still difficulties in the generation pathways, risk assessment, and control strategies for nitrosamine impurities. This article mainly introduces the possible nitrosation pathways and formation causes of nitrosamine impurities in chemical drugs, as well as the overall requirements for the analysis methods. And the risk assessment and control strategies for nitrosamine impurities in chemical drugs proposed by the regulatory agencies in various countries are summarized, which can provide a reference for further research and control of nitrosamine impurities.
In this study, the synthetic method of sparsentan(1) was improved. With 4-bromo-3-methylbenzo-nitrile(2) as the starting material, 3-(ethoxymethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde(6)was obtained via free radical substitution, nucleophilic substitution, cyano reduction, Miyaura borylation. In another way, the condensation of 2-bromobenzenesulfonyl chloride(7) with 3-amino-4,5-dimethylisoxazole(8) was conducted, followed by the amino-protection to give 2-bromo-N-(4,5-dimethylisoxazol-3-yl)-N-[(2-methoxyethoxy)methyl]benzene-sulfonamide(11). Intermediates 6 and 11 reacted via Suzuki coupling reaction to get N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-4'-formyl-N-[(2-methoxyethoxy)methyl]-[1,1'-biphenyl]-2-sulfonamide(12), then the target compound 1 was obtained from compound 12 via reduction, bromination, condensation and deprotection. The total yield was about 43.25%(based on 2) with the purity of 99.5%. The optimized route avoided the usage of the dangerous and toxic reagents such as n-butyl lithium and carbon tetrabromoide, and simplified some purifications.
In order to control the quality of fluticasone propionate, the synthesis route of impurity K(1) in EP of fluticasone propionate was designed. An economical and available starting material, dexamethasone (2), was acylated, chlorinated, hydrolyzed and deacetylated to obtain 6α-chloro-9α-fluoro -11β,17α,21-trihydroxy-16α-methyl-androstane-1,4-diene-3,20-dione(5). Then 5 was oxidized by periodic acid followed by the substitution with propionyl chloride to obtain 6α-chloro-9α-fluoro-11β-hydroxy-16α-methyl-17α-propoyloxy-3-oxandrostane-1,4-diene-17β-carboxylic acid(7). Then 7 underwent the rearrangement acylation reaction with N,N-dimethylthioformyl chloride, and then was hydrolyzed under alkaline conditions to obtain 6α-chloro-9α-fluoro-11β-hydroxy-16α-methyl-17α-propoyloxy-3-oxandrostane-1,4-diene-17β-carbothioic acid(9). Finally, the target product 1 was obtained by substituting 9 with bromofluoromethane under alkaline conditions. The total yield was about 48.34% (based on 2) with the purity more than 99%. This synthetic route of 1 was reported at the first time, which had certain reference significance for the synthesis of fluticasone propionate.
In order to control the quality of crisaborole(1) and its tablets, six related substances were synthesized based on the synthetic process of 1, namely 3-(4-cyanophenoxy)benzyl acetate(related substance A), 4,4'-di(4-cyanophenoxy)-2,2'-bis(acetoxymethyl)biphenyl(related substance B), 4,4'-di(4-cyanophenoxy)-2,2'-bis(hydroxymethyl)-biphenyl(related substance C), 4-[4-[4-bromo-3-(hydroxymethyl)phenoxy]-3-(hydroxymethyl)phenoxy]benzonitrile(related substance D), 5-[2-(acetoxymethyl)-4-(4-cyanophenoxy)phenoxy]-2-bromobenzyl acetate(related substance E)and 4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzoic acid(related substance F). Their structures were confirmed by 1H NMR, 13C NMR and MS, and the purities of all impurities were greater than 97%.